Nxera Pharma Co., Ltd. (TYO:4565)
Japan flag Japan · Delayed Price · Currency is JPY
1,680.00
-65.00 (-3.72%)
Nov 18, 2026, 10:40 AM JST

Nxera Pharma Statistics

Total Valuation

Nxera Pharma has a market cap or net worth of JPY 153.54 billion. The enterprise value is 188.88 billion.

Market Cap153.54B
Enterprise Value 188.88B

Important Dates

The last earnings date was Friday, October 30, 2026.

Earnings Date Oct 30, 2026
Ex-Dividend Date n/a

Share Statistics

Nxera Pharma has 91.39 million shares outstanding. The number of shares has increased by 0.77% in one year.

Current Share Class 91.39M
Shares Outstanding 91.39M
Shares Change (YoY) +0.77%
Shares Change (QoQ) +10.88%
Owned by Insiders (%) 9.20%
Owned by Institutions (%) 24.32%
Float 75.49M

Valuation Ratios

PE Ratio n/a
Forward PE 32.10
PS Ratio 4.49
PB Ratio 2.49
P/TBV Ratio n/a
P/FCF Ratio 31.81
P/OCF Ratio 28.46
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 39.49, with an EV/FCF ratio of 38.86.

EV / Earnings n/a
EV / Sales 5.49
EV / EBITDA 39.49
EV / EBIT n/a
EV / FCF 38.86

Financial Position

The company has a current ratio of 2.56, with a Debt / Equity ratio of 0.81.

Current Ratio 2.56
Quick Ratio 1.71
Debt / Equity 0.81
Debt / EBITDA 10.47
Debt / FCF 10.36
Interest Coverage 0.09

Financial Efficiency

Return on equity (ROE) is -8.31% and return on invested capital (ROIC) is 0.61%.

Return on Equity (ROE) -8.31%
Return on Assets (ROA) 0.28%
Return on Invested Capital (ROIC) 0.61%
Return on Capital Employed (ROCE) 0.54%
Weighted Average Cost of Capital (WACC) 6.95%
Revenue Per Employee 113.09M
Profits Per Employee -17.18M
Employee Count314
Asset Turnover 0.26
Inventory Turnover 0.59

Taxes

Income Tax -155.00M
Effective Tax Rate n/a

Stock Price Statistics

The stock price has increased by +103.14% in the last 52 weeks. The beta is 0.31, so Nxera Pharma's price volatility has been lower than the market average.

Beta (5Y) 0.31
52-Week Price Change +103.14%
50-Day Moving Average 1,365.40
200-Day Moving Average 1,069.50
Relative Strength Index (RSI) 65.27
Average Volume (20 Days) 2,327,640

Short Selling Information

Short Interest n/a
Short Previous Month n/a
Short % of Shares Out n/a
Short % of Float n/a
Short Ratio (days to cover) n/a

Income Statement

In the last 12 months, Nxera Pharma had revenue of JPY 35.51 billion and -5.39 billion in losses. Loss per share was -59.39.

Revenue35.51B
Gross Profit 29.19B
Operating Income 617.00M
Pretax Income -5.55B
Net Income -5.39B
EBITDA 4.96B
EBIT 617.00M
Loss Per Share -59.39
Full Income Statement

Balance Sheet

The company has 16.61 billion in cash and 51.96 billion in debt, with a net cash position of -35.34 billion or -386.73 per share.

Cash & Cash Equivalents 16.61B
Total Debt 51.96B
Net Cash -35.34B
Net Cash Per Share -386.73
Equity (Book Value) 64.15B
Book Value Per Share 701.96
Working Capital 24.00B
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 5.60 billion and capital expenditures -590.00 million, giving a free cash flow of 5.01 billion.

Operating Cash Flow 5.60B
Capital Expenditures -590.00M
Depreciation & Amortization 4.35B
Net Borrowing -16.04B
Free Cash Flow 5.01B
FCF Per Share 54.85
Full Cash Flow Statement

Margins

Gross margin is 82.20%, with operating and profit margins of 1.74% and -15.19%.

Gross Margin 82.20%
Operating Margin 1.74%
Pretax Margin -15.62%
Profit Margin -15.19%
EBITDA Margin 13.97%
EBIT Margin 1.74%
FCF Margin 14.12%

Dividends & Yields

Nxera Pharma does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
FCF Payout Ratio n/a
Buyback Yield -0.77%
Shareholder Yield -0.77%
Earnings Yield -3.53%
FCF Yield 3.14%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value n/a
Lynch Upside n/a
Graham Number n/a
Graham Upside n/a
Graham Formula Value n/a
Graham Formula Upside n/a

Analyst Forecast

The average price target for Nxera Pharma is 1,975.00, which is 17.56% higher than the current price. The consensus rating is "Buy".

Price Target 1,975.00
Price Target Difference 17.56%
Analyst Consensus Buy
Analyst Count 8
Revenue Growth Forecast (3Y) 19.15%
EPS Growth Forecast (3Y) n/a

Stock Splits

The last stock split was on June 27, 2018. It was a forward split with a ratio of 4.

Last Split Date Jun 27, 2018
Split Type Forward
Split Ratio 4

Scores

Nxera Pharma has an Altman Z-Score of 1.16 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score 1.16
Piotroski F-Score 6